Gilead Sciences Reports 2nd QTR Revenues of $1.28 Billion (Financial Report)
Biotech Financial Reports 2008, August 1, 15, 8
-
- $5.99
-
- $5.99
Publisher Description
Gilead Sciences, Inc.(Nasdaq: GILD), Foster City, Calif., has announced its results of operations for the quarter ended June 30, 2008. Total revenues for the second quarter of 2008 were $1.28 billion, up 22 percent compared to total revenues of $1.05 billion for the second quarter of 2007. Net income for the second quarter of 2008 was $442.8 million, or $0.46 per diluted share, including after-tax stock-based compensation expense of $26.4 million and after-tax purchased in-process research and development (IPR&D) expense of $7.8 million. Excluding after-tax stock-based compensation and IPR&D expenses of $34.2 million, non-GAAP net income for the second quarter of 2008 was $477.0 million, or $0.49 per diluted share. Non-GAAP net income for the second quarter of 2007 was $442.2 million, or $0.46 per diluted share, which excluded after-tax stock-based compensation expense of $34.3 million. Product Sales